237 related articles for article (PubMed ID: 24213314)
1. Remodeling of tumor stroma and response to therapy.
Johansson A; Ganss R
Cancers (Basel); 2012 Mar; 4(2):340-53. PubMed ID: 24213314
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine Strategies for Targeting Tumor Stroma.
Su MC; Nethi SK; Dhanyamraju PK; Prabha S
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627173
[TBL] [Abstract][Full Text] [Related]
3. Stromal integrin α11-deficiency reduces interstitial fluid pressure and perturbs collagen structure in triple-negative breast xenograft tumors.
Smeland HY; Lu N; Karlsen TV; Salvesen G; Reed RK; Stuhr L
BMC Cancer; 2019 Mar; 19(1):234. PubMed ID: 30876468
[TBL] [Abstract][Full Text] [Related]
4. Improving drug delivery to solid tumors: priming the tumor microenvironment.
Khawar IA; Kim JH; Kuh HJ
J Control Release; 2015 Mar; 201():78-89. PubMed ID: 25526702
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of hyaluronan in the tumor stroma.
Kultti A; Li X; Jiang P; Thompson CB; Frost GI; Shepard HM
Cancers (Basel); 2012 Sep; 4(3):873-903. PubMed ID: 24213471
[TBL] [Abstract][Full Text] [Related]
6. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways.
Yoshida GJ
J Exp Clin Cancer Res; 2020 Jun; 39(1):112. PubMed ID: 32546182
[TBL] [Abstract][Full Text] [Related]
7. Enhancing solid tumor therapy with sequential delivery of dexamethasone and docetaxel engineered in a single carrier to overcome stromal resistance to drug delivery.
Zhang L; Su H; Liu Y; Pang N; Li J; Qi XR
J Control Release; 2019 Jan; 294():1-16. PubMed ID: 30527754
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy.
Muntimadugu E; Kommineni N; Khan W
Pharmacol Res; 2017 Dec; 126():109-122. PubMed ID: 28511988
[TBL] [Abstract][Full Text] [Related]
9. The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells.
Mierke CT
Rep Prog Phys; 2019 Jun; 82(6):064602. PubMed ID: 30947151
[TBL] [Abstract][Full Text] [Related]
10. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
11. Normalization of the vasculature for treatment of cancer and other diseases.
Goel S; Duda DG; Xu L; Munn LL; Boucher Y; Fukumura D; Jain RK
Physiol Rev; 2011 Jul; 91(3):1071-121. PubMed ID: 21742796
[TBL] [Abstract][Full Text] [Related]
12. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance.
Dzobo K; Dandara C
OMICS; 2020 Jun; 24(6):314-339. PubMed ID: 32496970
[TBL] [Abstract][Full Text] [Related]
13. Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy.
Gkretsi V; Stylianou A; Papageorgis P; Polydorou C; Stylianopoulos T
Front Oncol; 2015; 5():214. PubMed ID: 26528429
[TBL] [Abstract][Full Text] [Related]
14. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment.
Menon H; Ramapriyan R; Cushman TR; Verma V; Kim HH; Schoenhals JE; Atalar C; Selek U; Chun SG; Chang JY; Barsoumian HB; Nguyen QN; Altan M; Cortez MA; Hahn SM; Welsh JW
Front Immunol; 2019; 10():193. PubMed ID: 30828330
[TBL] [Abstract][Full Text] [Related]
15. Emerging Nano Drug Delivery Systems Targeting Cancer-Associated Fibroblasts for Improved Antitumor Effect and Tumor Drug Penetration.
Guo J; Zeng H; Chen Y
Mol Pharm; 2020 Apr; 17(4):1028-1048. PubMed ID: 32150417
[TBL] [Abstract][Full Text] [Related]
16. The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.
Martinez-Outschoorn UE; Whitaker-Menezes D; Pavlides S; Chiavarina B; Bonuccelli G; Casey T; Tsirigos A; Migneco G; Witkiewicz A; Balliet R; Mercier I; Wang C; Flomenberg N; Howell A; Lin Z; Caro J; Pestell RG; Sotgia F; Lisanti MP
Cell Cycle; 2010 Nov; 9(21):4297-306. PubMed ID: 21051947
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies.
Mhaidly R; Mechta-Grigoriou F
Semin Immunol; 2020 Apr; 48():101417. PubMed ID: 33077325
[TBL] [Abstract][Full Text] [Related]
18. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
19.
Brassard-Jollive N; Monnot C; Muller L; Germain S
Front Cell Dev Biol; 2020; 8():594903. PubMed ID: 33224956
[No Abstract] [Full Text] [Related]
20. Gene expression profile of normal and cancer-associated fibroblasts according to intratumoral inflammatory cells phenotype from breast cancer tissue.
González L; Eiro N; Fernandez-Garcia B; González LO; Dominguez F; Vizoso FJ
Mol Carcinog; 2016 Nov; 55(11):1489-1502. PubMed ID: 26349857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
